Gilead 2026 outlook short of Wall Street view, shares dip

view original post

By Deena Beasley Feb 10 (Reuters) – Gilead Sciences on Tuesday issued a 2026 financial forecast that was at the low end of analysts’ expectations, including sales of its pioneering twice-yearly HIV …